NetworkNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Brings AI and Robotics Together in New Platform
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s launch of an AI-powered manufacturing services platform designed to help emerging biotechnology companies overcome one of the industry’s biggest challenges: accessing full GMP infrastructure. “The platform combines Oncotelic’s proprietary PDAOAI(TM) architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company’s strategic robotics and automation partner. The goal is not simply to apply AI to drug discovery, but to bring it into the manufacturing workflows that determine whether a therapy moves efficiently from development toward commercialization.”
Already deployed at Oncotelic’s GMP-certified SAPU manufacturing facility to support its own clinical pipeline, the platform “adds a second layer to the Oncotelic story. The company remains a clinical-stage biotech, but the AI-GMP platform could extend its role into enabling infrastructure for other drug developers. If adopted commercially, that creates a services-based revenue opportunity while strengthening Oncotelic’s internal development engine. Combined with TechForce Robotics’ automation capabilities, the launch reflects a broader industry shift toward intelligent manufacturing systems that reduce manual workload and tighten compliance discipline.”
To view the full article, visit https://nnw.fm/8gG3l
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s launch of an AI-powered manufacturing services platform designed to help emerging biotechnology companies overcome one of the industry’s biggest challenges: accessing full GMP infrastructure. “The platform combines Oncotelic’s proprietary PDAOAI(TM) architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company’s strategic robotics and automation partner. The goal is not simply to apply AI to drug discovery, but to bring it into the manufacturing workflows that determine whether a therapy moves efficiently from development toward commercialization.”
Already deployed at Oncotelic’s GMP-certified SAPU manufacturing facility to support its own clinical pipeline, the platform “adds a second layer to the Oncotelic story. The company remains a clinical-stage biotech, but the AI-GMP platform could extend its role into enabling infrastructure for other drug developers. If adopted commercially, that creates a services-based revenue opportunity while strengthening Oncotelic’s internal development engine. Combined with TechForce Robotics’ automation capabilities, the launch reflects a broader industry shift toward intelligent manufacturing systems that reduce manual workload and tighten compliance discipline.”
To view the full article, visit https://nnw.fm/8gG3l
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
